Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)

NCT01064349 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01064349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01064349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
May 6, 2009
Completion date
June 3, 2011
Enrollment
144 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer